Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07535034 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
A Phase 2 study, sponsored by Crystalys Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07535034 is a Phase 2 study that is actively recruiting participants, run by Crystalys Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT07535034, a Phase 2 study, is actively recruiting participants, sponsored by Crystalys Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
Interventions
- OTHER Placebo
- DRUG Dotinurad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-05-08 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07535034
The ClinicalTrials.gov registry entry for NCT07535034 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crystalys Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07535034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07535034 about?
NCT07535034 is a clinical study titled "A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants". The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
What is the current status of trial NCT07535034?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-05-08. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07535034?
The interventions under investigation include: Placebo (OTHER), Dotinurad (DRUG).
Who is sponsoring clinical trial NCT07535034?
This trial is sponsored by Crystalys Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.